黒色腫治療薬の世界市場予測および分析...市場調査レポートについてご紹介

【英文タイトル】PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2023

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 26
2.1 Catalyst 26
2.2 Related Reports 27
2.3 Upcoming Related Reports 27
3 Disease Overview 28
3.1 Etiology and Pathophysiology 28
3.1.1 Etiology 28
3.1.2 Pathophysiology 28
3.1.3 Melanoma Biomarkers 29
3.2 Clinical Staging 30
3.3 Symptoms 32
3.4 Prognosis 32
3.5 Quality of Life 34
4 Epidemiology 35
4.1 Disease Background 35
4.2 Risk Factors and Comorbidities 35
4.3 Global Trends 38
4.3.1 US 39
4.3.2 5EU 39
4.3.3 Japan and Australia 39
4.4 Forecast Methodology 40
4.4.1 Sources Used 42
4.4.2 Sources Not Used 49
4.4.3 Forecast Assumptions and Methods 49
4.5 Epidemiological Forecast for Melanoma (2013-2023) 52
4.5.1 Diagnosed Incident Cases of Melanoma 52
4.5.2 Age-Specific Diagnosed Incident Cases of Melanoma 54
4.5.3 Sex-Specific Diagnosed Incident Cases of Melanoma Skin Cancer 56
4.5.4 Age-Standardized Diagnosed Incidence Rates 58
4.5.5 Pathological Stage at Diagnosis 60
4.5.6 Five-Year Diagnosed Prevalent Cases of Melanoma Skin Cancer 61
4.5.7 Five-Year Diagnosed Prevalent Cases of Melanoma Skin Cancer by Genetic Aberrations 63
4.6 Discussion 65
4.6.1 Epidemiological Forecast Insight 65
4.6.2 Limitations of the Analysis 66
4.6.3 Strengths of the Analysis 67
5 Disease Management 68
5.1 Diagnosis Overview 68
5.2 Treatment Overview 69
5.2.1 Localized Melanoma: Stage 0 to Stage IIC 71
5.2.2 Regional Melanoma: Stage IIIA to Stage IIIC 72
5.2.3 Unresectable and Metastatic Melanoma: Stage III and Stage IV 75
5.3 US 81
5.3.1 Screening and Diagnosis 82
5.3.2 Clinical Practices 84
5.4 France 86
5.4.1 Screening and Diagnosis 87
5.4.2 Clinical Practices 87
5.5 Germany 88
5.5.1 Screening and Diagnosis 89
5.5.2 Clinical Practices 90
5.6 Italy 93
5.6.1 Screening and Diagnosis 94
5.6.2 Clinical Practices 94
5.7 Spain 96
5.7.1 Screening and Diagnosis 97
5.7.2 Clinical Practices 97
5.8 UK 98
5.8.1 Screening and Diagnosis 99
5.8.2 Clinical Practices 99
5.9 Japan 101
5.9.1 Screening and Diagnosis 101
5.9.2 Clinical Practices 102
5.10 Australia 103
5.10.1 Screening and Diagnosis 104
5.10.2 Clinical Practices 105
6 Competitive Assessment 108
6.1 Overview 108
6.2 Interferon-based Adjuvant Therapies 110
6.2.1 Roferon-A (Interferon Alfa-2a) 110
6.2.2 Intron A (Interferon Alfa-2b) 114
6.2.3 Sylatron (Peginterferon Alfa-2b) 118
6.3 Immune Checkpoint Inhibitors 124
6.3.1 Yervoy (Ipilimumab) 124
6.3.2 Opdivo (Nivolumab) 134
6.3.3 Keytruda (Pembrolizumab) 143
6.4 BRAF Mutation-targeted Therapies 151
6.4.1 Zelboraf (Vemurafenib) 151
6.4.2 Tafinlar (Dabrafenib) 158
6.4.3 Mekinist (Trametinib) 164
6.5 Other Therapeutic Classes 176
7 Unmet Need and Opportunity 178
7.1 Overview 178
7.2 Therapeutic Options for BRAF Wild-Type Patients 180
7.2.1 Unmet Need 180
7.2.2 Gap Analysis 181
7.2.3 Opportunity 182
7.3 Therapies for Non-responders to PD-1 Immunotherapy 183
7.3.1 Unmet Need 183
7.3.2 Gap Analysis 184
7.3.3 Opportunity 186
7.4 Adjuvant Therapies for High-Risk Resectable Melanoma 188
7.4.1 Unmet Need 188
7.4.2 Gap Analysis 189
7.4.3 Opportunity 191
7.5 Effective Treatment for Brain Metastases 193
7.5.1 Unmet Need 193
7.5.2 Gap Analysis 194
7.5.3 Opportunity 196
7.6 Predictive Markers for Therapeutic Response to Immunotherapies 197
7.6.1 Unmet Need 197
7.6.2 Gap Analysis 198
7.6.3 Opportunity 200
8 Pipeline Assessment 201
8.1 Overview 201
8.2 Promising Drugs in Clinical Development 202
8.3 RAF/RAS/MEK Pathway-Targeting Therapies 204
8.3.1 Cobimetinib (GDC-0973) 204
8.3.2 Encorafenib (LGX818) 211
8.3.3 Binimetinib (MEK162) 217
8.4 Immune-Related Therapies 224
8.4.1 Talimogene Laherparepvec 224
8.4.2 Eltrapuldencel-T (NSB20) 232
8.4.3 Seviprotimut-L (POL-103A) 238
8.4.4 PV-10 244
8.5 Promising Drugs in Early-Stage Development 250
8.5.1 PI3K/Akt/mTOR Pathway-Targeting Therapies 250
8.5.2 Cell Cycle Checkpoint Inhibitors 252
8.5.3 Next-Generation BRAF Inhibitors 254
8.5.4 Immunotherapies 256
8.5.5 Antibody-Drug Conjugates 259
8.6 Other Drugs in Development 261
9 Current and Future Players 263
9.1 Overview 263
9.2 Trends in Corporate Strategy 266
9.3 Company Profiles 267
9.3.1 Bristol-Myers Squibb 267
9.3.2 Novartis 270
9.3.3 Roche 273
9.3.4 Merck 276
10 Market Outlook 280
10.1 Global Markets 280
10.1.1 Forecast 280
10.1.2 Drivers and Barriers — Global Issues 284
10.2 United States 286
10.2.1 Forecast 286
10.2.2 Key Events 290
10.2.3 Drivers and Barriers — US 291
10.3 5EU 293
10.3.1 Forecast 293
10.3.2 Key Events 297
10.3.3 Drivers and Barriers — France 298
10.3.4 Drivers and Barriers — Germany 300
10.3.5 Drivers and Barriers — Italy 301
10.3.6 Drivers and Barriers — Spain 303
10.3.7 Drivers and Barriers — UK 304
10.4 Japan 306
10.4.1 Forecast 306
10.4.2 Key Events 309
10.4.3 Drivers and Barriers — Japan 309
10.5 Australia 311
10.5.1 Forecast 311
10.5.2 Key Events 314
10.5.3 Drivers and Barriers — Australia 315
11 Appendix 317
11.1 Bibliography 317
11.2 Abbreviations 344
11.3 Methodology 349
11.4 Forecasting Methodology 349
11.4.1 Diagnosed Melanoma Patients 349
11.4.2 Percent Drug-Treated Patients 350
11.4.3 Drugs Included in Each Therapeutic Class 350
11.4.4 Launch and Patent Expiry Dates 351
11.4.5 General Pricing Assumptions 352
11.4.6 Average Body Weight and Surface Area Across the 8MM 353
11.4.7 Individual Drug Assumptions 354
11.4.8 Generic Erosion 368
11.4.9 Pricing of Pipeline Agents 368
11.5 Primary Research – KOLs Interviewed for this Report 370
11.6 Primary Research – Prescriber Survey 373
11.7 About the Authors 374
11.7.1 Analyst 374
11.7.2 Therapy Area Director 374
11.7.3 Epidemiologist 375
11.7.4 Global Head of Healthcare 375
11.8 About GlobalData 376
11.9 Disclaimer 376


【レポート販売概要】

■ タイトル:黒色腫治療薬の世界市場予測および分析
■ 英文:PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2023
■ 発行日:2015年4月5日
■ 調査会社:GlobalData
■ 商品コード:GDHC104PIDR
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。